
到 2028 年南美洲胰岛素市场预测 - COVID-19 影响和区域分析 - 按类型(长效胰岛素、速效胰岛素、短效胰岛素和传统人胰岛素、浓缩胰岛素和组合胰岛素、生物仿制药胰岛素、胰高血糖素)如肽-1 (GLP-1)、笔和针等)
No. of Pages: 177 | Report Code: BMIRE00027250 | Category: Life Sciences
No. of Pages: 177 | Report Code: BMIRE00027250 | Category: Life Sciences
SAM 的胰岛素市场
预计将从 2022 年的 48.6881 亿美元增长到 2028 年的 89.3046 亿美元。预计将以2022 年至 2028 年复合年增长率为 10.6%。
胰岛素输送设备技术的快速发展主要参与者
采用先进胰岛素技术、具有更有效功效的产品是治疗以下疾病的主要要求糖尿病。过去几年,糖尿病治疗取得了长足的进步。随着整个地区糖尿病患病率的增加,对更先进产品的需求也在增加。由于行业参与者加大战略力度,胰岛素市场预计将增长。市场参与者积极支持其公共和私人研究和学术机构增加研究活动。
下面提到了与胰岛素市场快速技术进步相关的一些最新发展:
• 2021年10月,通化东宝药业股份有限公司的超速效赖脯胰岛素注射液BC Lispro获得国家药品监督管理局(NMPA)批准开展临床试验。目前该药物正在国内启动Ⅲ期临床试验。
• 2021 年 5 月,Bigfoot Biomedical 的 Bigfoot Unity 糖尿病管理系统获得美国 FDA 510(k) 批准,该系统具有联网智能笔帽,可为使用每日多次注射 (MDI) 疗法的患者推荐胰岛素剂量。
因此,胰岛素输送设备的快速技术进步正在推动 SAM 胰岛素市场的增长。
< strong>市场概览
SAM 胰岛素市场分为阿根廷、巴西和 SAM 的其他地区。市场增长归因于该地区糖尿病(I 型和 II 型)发病率的增加。此外,有利于胰岛素制造商运营的监管框架鼓励各种跨国公司在 SAM 国家建立生产单位。据国际糖尿病联合会称,2021 年,SAM 地区有 3300 万成年人(20-79 岁)患有糖尿病。预计到 2030 年,这一数字将增至 4000 万,到 2045 年将增至 4900 万。根据该报告,1570 万成年人患有糖尿病。在巴西,十分之一的成年人患有糖尿病。糖尿病发病率的不断上升导致患者生活质量的下降。 《全球健康年鉴》发表文章称,2019年11月,糖尿病流行影响全球大多数国家,拉丁美洲国家感染率惊人。巴西约有 1200 万人患有糖尿病,目前患病率在 6.3% 至 13.5% 之间。糖尿病患病率的上升进一步导致与糖尿病相关的心血管疾病的相关风险比增加了 60%。
SAM 胰岛素市场按类型和国家/地区进行细分。根据类型,市场分为长效胰岛素、速效胰岛素、短效胰岛素和短效胰岛素。传统人胰岛素、浓缩胰岛素和胰岛素组合胰岛素、生物仿制药胰岛素、胰高血糖素样肽-1 (GLP-1)、pen &针等。长效胰岛素细分市场在 2022 年占据最大市场份额。
Biocon;礼来公司;葛兰素史克公司;默克公司有限公司;诺和诺德公司;辉瑞公司;赛诺菲;通化东宝药业有限公司;和 Wockhardt 是该地区胰岛素市场的领先公司。
Strategic insights for South America Insulin involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 4,868.81 Million |
Market Size by 2028 | US$ 8,930.46 Million |
Global CAGR (2022 - 2028) | 10.6% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 类型
|
Regions and Countries Covered | 南美洲和中美洲
|
Market leaders and key company profiles |
The regional scope of South America Insulin refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The South America Insulin Market is valued at US$ 4,868.81 Million in 2022, it is projected to reach US$ 8,930.46 Million by 2028.
As per our report South America Insulin Market, the market size is valued at US$ 4,868.81 Million in 2022, projecting it to reach US$ 8,930.46 Million by 2028. This translates to a CAGR of approximately 10.6% during the forecast period.
The South America Insulin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South America Insulin Market report:
The South America Insulin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South America Insulin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South America Insulin Market value chain can benefit from the information contained in a comprehensive market report.